Oversold Stocks In News: Halozyme Therapeutics (NASDAQ:HALO), Lumos Networks (NASDAQ:LMOS), Advaxis (NASDAQ:ADXS), Sterling Construction Company (NASDAQ:STRL)

Halozyme Therapeutics, Inc. (NASDAQ:HALO) reported that the U.S. Food and Drug Administration ordered a halt on a study of its drug delivery system in pancreatic cancer patients, barely a week after the company voluntarily stopped the trial. Halozyme Therapeutics, Inc. (NASDAQ:HALO) stock performance was -0.93% in last session and finished the day at $7.42. Traded volume was 3.20million shares in the last session and the … Continue reading Oversold Stocks In News: Halozyme Therapeutics (NASDAQ:HALO), Lumos Networks (NASDAQ:LMOS), Advaxis (NASDAQ:ADXS), Sterling Construction Company (NASDAQ:STRL)

Jayne Crisman04/1404/14

Biotech Active runners: Arena Pharmaceuticals (NASDAQ:ARNA), Halozyme Therapeutics (NASDAQ:HALO), Gildan Activewear (NYSE:GIL), Ariad Pharmaceuticals (NASDAQ:ARIA)

Sales of the Arena Pharmaceuticals Inc (NASDAQ:ARNA) anti-obesity drug Belviq have closed out the quarter on a positive note. Sales improved throughout the quarter and are pacing well ahead of the previous quarter. Though this week’s sales only take us to March 28th, there is enough here for us to assess the sales activity, project some revenue, and look to the pace. Arena Pharmaceuticals, Inc. … Continue reading Biotech Active runners: Arena Pharmaceuticals (NASDAQ:ARNA), Halozyme Therapeutics (NASDAQ:HALO), Gildan Activewear (NYSE:GIL), Ariad Pharmaceuticals (NASDAQ:ARIA)

Jason Knox04/0704/07

Biotech Volatile Stocks: Incyte Corporation (NASDAQ:INCY), Halozyme Therapeutics (NASDAQ:HALO), Sangamo Biosciences (NASDAQ:SGMO), Nektar Therapeutics (NASDAQ:NKTR)

The only therapy currently approved by the Food and Drug Administration to treat myelofibrosis, a disorder where abnormal blood cells build up inside a patient’s bone marrow, is Incyte (NASDAQ:INCY) and Novartis’ Jakafi (known as Jakavi outside the U.S.), which is a JAK2 inhibitor. JAK2 is an enzyme that plays a key role in signal transduction; therefore, blocking JAK2 can inhibit the development cytokines that … Continue reading Biotech Volatile Stocks: Incyte Corporation (NASDAQ:INCY), Halozyme Therapeutics (NASDAQ:HALO), Sangamo Biosciences (NASDAQ:SGMO), Nektar Therapeutics (NASDAQ:NKTR)

Mark Doerr03/2503/25

Biotech Losers: Novavax (NASDAQ:NVAX), Achillion Pharmaceuticals (NASDAQ:ACHN), The Clorox (NYSE:CLX), Halozyme Therapeutics (NASDAQ:HALO)

Novavax, Inc. (NASDAQ:NVAX) is a vaccine company that is likely to have multiple milestones this year. It has U.S. government funding for seasonal and pandemic flu, and is developing its own products for respiratory syncytial virus (RSV). Novavax, Inc. (NASDAQ:NVAX) stock performance was -5.02% in last session and finished the day at $6.05. Traded volume was 4.36million shares in the last session and the average … Continue reading Biotech Losers: Novavax (NASDAQ:NVAX), Achillion Pharmaceuticals (NASDAQ:ACHN), The Clorox (NYSE:CLX), Halozyme Therapeutics (NASDAQ:HALO)

Mark Doerr03/0703/07

Biotech Gainers: Insys Therapeutics Inc (NASDAQ:INSY), Oxygen Biotherapeutics (NASDAQ:OXBT), Halozyme Therapeutics (NASDAQ:HALO), Cytori Therapeutics (NASDAQ:CYTX)

Insys Therapeutics (NASDAQ:INSY) hit a new 52-week high during trading on Tuesday following a better than expected earnings announcement, AnalystRatings.NET reports. Insys Therapeutics Inc (NASDAQ:INSY) stock performance was 21.73% in last session and finished the day at $83.37. Traded volume was 1,203,992 million shares in the last session and the average volume of the stock remained 263.48 million shares. The beta of the stock remained … Continue reading Biotech Gainers: Insys Therapeutics Inc (NASDAQ:INSY), Oxygen Biotherapeutics (NASDAQ:OXBT), Halozyme Therapeutics (NASDAQ:HALO), Cytori Therapeutics (NASDAQ:CYTX)

Mark DeFrance03/0503/05

Stocks Getting Investor’s Attention: BP p.l.c. (NYSE:BP), Yahoo! Inc. (NASDAQ:YHOO), Pall Corporation (NYSE:PLL), Halozyme Therapeutics, Inc. (NASDAQ:HALO), Alliance One International, Inc. (NYSE:AOI)

BP p.l.c. (NYSE:BP) Chief Executive Bob Dudley told staff in a Monday memo that the company would freeze 2015 base pay, part of a larger round of cost savings and cuts the company has undertaken as oil prices remain at less than half the level of mid-2014, a BP spokesman said. BP p.l.c. (NYSE:BP) belongs to Basic Materials sector. Its net profit margin is 2.50% … Continue reading Stocks Getting Investor’s Attention: BP p.l.c. (NYSE:BP), Yahoo! Inc. (NASDAQ:YHOO), Pall Corporation (NYSE:PLL), Halozyme Therapeutics, Inc. (NASDAQ:HALO), Alliance One International, Inc. (NYSE:AOI)

Colin Pettis01/2701/27